

Specimen Collected: 02-Sep-20 10:54

1p/19q, FISH	Result	Units	Received: 02-Sep-20 10:57	Report/Verified: 14-Sep-20 11:31
				Reference Interval
1p Result	Deleted			
19q Result	Deleted ^{f1 i1}			
1p/1q Ratio	0.50			
Chromosome 1 Polysomy	Not Detected			
19q/19p Ratio	0.47			
Chromosome 19 Polysomy	Not Detected			
1p19q FISH Reference Number				
1p19q FISH Source	Brain			
1P Total Cell Count	50			
19Q Total Cell Count	50			
Scoring Method	Manual			

IDH1 by IHC with Reflex and 1P19Q FISH	Result	Units	Received: 02-Sep-20 10:57	Report/Verified: 14-Sep-20 11:31
				Reference Interval
Block ID				
IDH1 R132H Point Mut by IHC with Reflex	Positive ^{f2 i2}			
IDH1 Tissue Source	Brain			

Result Footnote

f1: 19q Result

This result has been reviewed and approved by Deepika Sirohi, M.D. Controls performed as expected.

f2: IDH1 R132H Point Mut by IHC with Reflex

Controls were run and performed as expected.

This result has been reviewed and approved by Christian J. Davidson, M.D.

2000 Circle of Hope, RM 3100

Salt Lake City, UT 84112

Test Information

i1: 19q Result

INTERPRETIVE INFORMATION: 1p/19q, FISH

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block using differentially labeled fluorescent probes targeting 1p36/1q25 and 19p13/19q13 (Abbott Molecular). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin- and eosin-stained section. Controls performed appropriately.

This assay evaluates the average ratios of 1p to 1q and 19q to 19p, as well as the percentage of cells with a signal pattern consistent with a deletion (individual cell 1p/1q and 19q/19p ratios of 0.5 or lower). Based on the validation of this assay, 1p deletion is defined as a 1p/1q ratio below 0.80 combined with a deleted

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing Lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 20-246-900189

Report Request ID: 13678063

Printed: 16-Sep-20 16:02

Page 1 of 3

Test Information

i1: 19q Result
 pattern in 24 percent or more of the scored cells, and 19q deletion is defined as a 19q/19p ratio below 0.80 combined with a deleted pattern in 26 percent or more of the scored cells.

Codeletion of 1p and 19q as the result of an unbalanced translocation is characteristic of oligodendrogliomas and a diagnostic feature according to the WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition (2016).

Codeletion is also predictive of a favorable response to combination chemotherapy. Isolated deletions of 1p or 19q are neither diagnostic nor predictive in a similar fashion. Polysomy, defined in this context as three or more signals for 1q and/or 19p in 30 percent or more of the tumor cells, suggests a less-favorable outcome in oligodendrogliomas. Based on the assay performance during test validation, the test is expected to detect 96 percent of 1p and 19q deletions in patients with oligodendrogliomas. Assay range and limit of detection were generated using normal and known positive cases respectively. Correlation with other laboratory data, especially histopathologic findings, is recommended for optimal risk stratification.

References:

- Jenkins RB et al. A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. *Cancer Res* 66 (20): 9852-9861, 2006.
- Snuderl M et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. *Clin Cancer Res* 15(20):6430-6437, 2009.
- Wiens et al. Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. *J Neuropathol Exp Neurol* 71(7):618-624, 2012.
- Clark K et al. How molecular testing can help (and hurt) in the workup of gliomas. *Am J Clin Pathol* 139(3):275-288, 2013.
- Senetta R et al. A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors. *J Neuropathol Exp Neurol* 72(5):432-41, 2013.
- Eckel-Passow JE et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med* 25;372(26):2499-508, 2015.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A, Eds. WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition. Lyon, France: International Agency for Research on Cancer, 2016.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: aruplab.com/CS

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing Lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 20-246-900189

Report Request ID: 13678063

Printed: 16-Sep-20 16:02

Page 2 of 3

Test Information

i2: IDH1 R132H Point Mut by IHC with Reflex

INTERPRETIVE INFORMATION: IDH1 R132H Point Mut by IHC
with Reflex

IDH1 R132H Point Mutation by Immunohistochemistry detects the presence of mutant IDH1 R132H protein expression in diffuse gliomas and can serve as a screening tool for molecular testing. A positive result indicates a probable IDH1 R132H mutation. A negative result indicates the tumor has no R132H mutation, which will automatically reflex to IDH1 and IDH2 gene sequencing, to detect less common IDH1 or IDH2 mutations not detected by the IHC test. This test is performed on paraffin-embedded, formalin-fixed tissue.

Controls were run and performed as expected.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing Lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 20-246-900189

Report Request ID: 13678063

Printed: 16-Sep-20 16:02

Page 3 of 3